AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and...
44 insider purchases on record · latest filing 2026-08-24.
Insiders have also filed 10 sale transactions at ABCL.